Menu

#Alpha

4443 posts

Suggested profile:👤 Alpha
Feed·
17 of 4443 posts
ImmunityBio: Q3 ANKTIVA Slowdown And Cash Burn Reaffirm My Sell Rating
🖼️
0Read More

ImmunityBio: Q3 ANKTIVA Slowdown And Cash Burn Reaffirm My Sell Rating

All Articles on Seeking Alpha·about 8 hours ago
#nwlQwgXu
#seekingalpha#investment#seeking#alpha#sell

ImmunityBio remains a Sell as slowing ANKTIVA sales, unproven pipeline potential, widening losses, and dilution risks challenge its $7B valuation.

15s
Alphabet: A 30% Decline From All-Time High Is Probably Not Enough
🖼️
0Read More

Alphabet: A 30% Decline From All-Time High Is Probably Not Enough

All Articles on Seeking Alpha·about 8 hours ago
#L07pWRGR

The bear case on Alphabet: DCF values shares at $212.20; heavy AI capex, negative free cash flow and uncertain monetization leave the stock overvalued.

15s
Essex Property Trust: Q3 Performance Underpins The Bet On Quality West Coast Portfolio
🖼️
0Read More

Essex Property Trust: Q3 Performance Underpins The Bet On Quality West Coast Portfolio

All Articles on Seeking Alpha·about 8 hours ago
#sqzTQ5Rd

ESS gets a buy for my initial rating. Strengths are a favorable supply/demand scenario, proven resilience over 5 years, and Q3 performance.

15s
Lumentum: The Drawdown Might Have Gone Too Far (Rating Upgrade)
🖼️
0Read More

Lumentum: The Drawdown Might Have Gone Too Far (Rating Upgrade)

All Articles on Seeking Alpha·about 8 hours ago
#QsvcV5Db
#seekingalpha#seeking#alpha#deal#companies

Analyst rates Lumentum a Hold: a nearly 35% decline and 136% Q1 revenue growth correct prior overvaluation; shares trade 16.5% below deal value.

15s
My Favorite Place To Buy Income: 2 Strong Buys After The Sell-Off
🖼️
0Read More

My Favorite Place To Buy Income: 2 Strong Buys After The Sell-Off

All Articles on Seeking Alpha·about 8 hours ago
#DQK8lpZY
#seekingalpha#high#growth#yield#seeking

Two attractive high-yield opportunities have recently sold off sharply, creating what I believe are compelling entry points for patient, long-term investors.

15s
Oaktree Specialty Lending: Another Dividend Cut Is Likely Coming (Rating Downgrade)
🖼️
0Read More

Oaktree Specialty Lending: Another Dividend Cut Is Likely Coming (Rating Downgrade)

All Articles on Seeking Alpha·about 8 hours ago
#pDIepLUZ

Analyst rates Oaktree Specialty Lending a Sell: shrinking supplemental dividends and weaker coverage could raise 2027 dividend-cut risk at a 24% NAV...

15s
Treasury Bonds At 5%: Dividend Stocks Are Still Worth It
🖼️
0Read More

Treasury Bonds At 5%: Dividend Stocks Are Still Worth It

All Articles on Seeking Alpha·about 8 hours ago
#wbtmtbDm
#seekingalpha#seeking#alpha#yield#investor

The bull case for dividend stocks over 5% Treasury yields: dividend growth can boost long-term returns, and low valuations could add upside.

15s
Williams-Sonoma: Beautiful Business, But Elevated Valuation
🖼️
0Read More

Williams-Sonoma: Beautiful Business, But Elevated Valuation

All Articles on Seeking Alpha·about 8 hours ago
#qgs8nO8C
#seekingalpha#investment#seeking#alpha#advice

Analyst rates Williams-Sonoma a Hold: at 28x forward earnings, shares could face multiple compression as Q3 margin fell 20 bps to 17%.

15s
Vertex Pharmaceuticals: Look For Povetacicept Approval In 2 Weeks As Next Catalyst
🖼️
0Read More

Vertex Pharmaceuticals: Look For Povetacicept Approval In 2 Weeks As Next Catalyst

All Articles on Seeking Alpha·about 8 hours ago
#xyMffPue

Analyst rates Vertex Pharmaceuticals Incorporated a Buy: CF is an estimated 60% of market value, and its pipeline could support long-term market outperformance.

15s
Patience In Gold Paid Off, Now Let's Get Bullish
🖼️
0Read More

Patience In Gold Paid Off, Now Let's Get Bullish

All Articles on Seeking Alpha·about 8 hours ago
#BiCBu25v
#seekingalpha#gold#seeking#alpha#investors

The bull case for gold: the writer sees the forecast cut as a contrarian buying opportunity after the correction, with central banks still net buyers.

15s
Medical Properties Trust: 22% Yield? Not According To The Chart
🖼️
0Read More

Medical Properties Trust: 22% Yield? Not According To The Chart

All Articles on Seeking Alpha·about 8 hours ago
#gCPEk6zQ

Analyst rates MPT a Hold: Q3 normalized FFO fell to $0.11, while 8.7x leverage and an uncovered dividend outweigh its 22.64% yield.

15s
KORU Medical Systems, Inc. (KRMD) Presents at Craig-Hallum 17th Annual Alpha Select Conference - Slideshow
🖼️
0Read More

KORU Medical Systems, Inc. (KRMD) Presents at Craig-Hallum 17th Annual Alpha Select Conference - Slideshow

All Articles on Seeking Alpha·about 20 hours ago
#3UfnVldL

2026-11-19. The following slide deck was published by KORU Medical Systems, Inc.

15s
Novo Nordisk: A Return To Growth May Be Just Around The Corner
🖼️
0Read More

Novo Nordisk: A Return To Growth May Be Just Around The Corner

All Articles on Seeking Alpha·about 20 hours ago
#LW9k97K6
#seekingalpha#stock#seeking#alpha#investors

Analyst rates Novo Nordisk A/S a Buy, calling its 10–11x forward P/E inexpensive; stronger-than-expected 2027 guidance could restore momentum.

15s
Lionsgate's Hunger For Consolidation
🖼️
0Read More

Lionsgate's Hunger For Consolidation

All Articles on Seeking Alpha·about 20 hours ago
#HbpwZlbl
#seekingalpha#stock#lion#seeking#alpha

Analyst rates Lionsgate a Hold: no buyout offer has emerged; cash-flow concerns persist as the prolonged M&A process raises holding risk in a weak market.

15s